This study tests a drug called Remternetug (LY3372993) for early Alzheimer's Disease (AD), which affects memory and thinking. The study compares Remternetug to a placebo (a harmless, inactive substance). It aims to see if Remternetug helps delay or prevent memory and thinking problems.

The study lasts up to 255 weeks, which includes different phases like screening, treatment, and observation. Participants who initially receive a placebo may later get the actual drug. To join, you need to have certain test results and a partner who knows you well. People with serious illnesses or other conditions that might interfere with the study can't participate.

• Duration: Participation could last nearly 5 years (255 weeks).
• Visits: Various visits required during the study phases.
• Eligibility: Specific criteria must be met, such as no severe allergies or other conditions.

Discuss with your doctor if this study is suitable for you, especially if you have early AD and meet the necessary criteria.